优化布洛普封装双胞胎细胞的增强行为影响,而不是传统的治疗抑郁症的尼奥组
Karthick Harini1, Koyeli Girigoswami1, Mohammed Vajagathali1
1Medical Bionanotechnology, Faculty of Allied Health Sciences (FAHS), Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, TN-603103, India.
Naunyn-Schmiedeberg's archives of pharmacology
|October 30, 2024
概括
这项研究使用双体囊泡开发了一种布洛普 (Bpn) 纳米配方,增强其抗抑郁作用并降低毒性. 与传统方法相比,这种新的配方显示出改善大脑传递和情绪提升的承诺.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 神经药理学神经药理学
背景情况:
- 布鲁 (Bpn) 是FDA批准的诺亚上腺素-多巴胺再吸收抑制剂 (NDRI),具有发作和肝衰竭的风险.
- 由于Bpn具有刺激性,因此需要开发更安全,更有效的替代配方.
- 新型纳米配方对于提高治疗疗效和减少现有药物的不良影响至关重要.
研究的目的:
- 为了开发一个布洛普纳米配方封装在双体囊泡内.
- 在较低剂量下增强布洛普里昂的治疗疗效.
- 为了评估新型双体体配方的稳定性,毒性和体内疗效.
主要方法:
- 布鲁纳米配方使用双体囊泡通过薄膜水化与跨度20表面活性剂,胆固醇和胆酸盐制备.
- 通过不同的成分度,比洛索姆配方的稳定性得到了优化.
- 评估了封装效率,药物保留能力,体外/体内毒性以及人工脑脊液 (ACSF) 中的释放特征.
- 斑马鱼模型被用于体内行为分析,以评估抗抑郁药物的效果.
主要成果:
- 优化表面活性剂与胆固醇与胆汁盐的比例为1.5:1:0.17μM,产生了最稳定的胆固体系统 (B.SCF).
- 与尼体相比,装有布洛的双体囊泡 (Bpn@B.SCF) 显示出高封装效率 (78.14 ± 11.07%) 和优越的药物保留率.
- Bpn@B.SCF配方在体外和体内的毒性是可以忽略不计的 (活力≥95%),并且在ACSF中持续释放.
- 在体内研究表明,Bpn@B.SCF显著改善了斑马鱼的抑郁行为,由增加的探索和减少不规则的运动证明.
结论:
- 比洛索姆囊泡代表比尼奥索姆相比布普罗的药物递送系统优越,促进大脑递送的增强.
- 开发的布洛双体纳米配方 (Bpn@B.SCF) 提供了改善的治疗疗效和有利的安全性.
- 这种新的配方有可能更有效地改善情绪和治疗抑郁症,并减少副作用.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
196
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
196
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
320
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
320
01:25Antidepressant Drugs: Overview
370
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
370
01:19Management of Insomnia
234
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
234
01:21Drugs for Treatment of Constipation-Predominant IBS
139
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
139
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
745
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
745